Pfizer Leaves Itself Open To Possible Sales Force Reductions
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has backed away from its earlier position that any reductions would be unlikely. The follows another quarter of lackluster performances by the recently launched Caduet and Inspra.
You may also be interested in...
Novartis Will Stand Tough On Sales Force Size, CEO Costa Says
Potential cuts to competitors' sales forces will give Novartis an opportunity to "leverage that asset," the exec says. Novartis' sales force continues to offer a strong return on investment, he notes.
Novartis Will Stand Tough On Sales Force Size, CEO Costa Says
Potential cuts to competitors' sales forces will give Novartis an opportunity to "leverage that asset," the exec says. Novartis' sales force continues to offer a strong return on investment, he notes.
GSK Will Cut Sales Force And Reinvest In R&D If Pfizer Acts First
Company would “welcome” a decision by Pfizer to cut back its sales force, CEO Garnier declares. Analyst reports have ignited market speculation that Pfizer is ready to retool its sales and marketing infrastructure.